bullish

GNI Group

GNI Placement: Easy to Digest but Not Without Small Cap Pharma Risks

463 Views23 Jul 2025 08:49
GNI is looking to raise around US$100m from a primary placement (after upsize). In this note, we will talk about the placement and run the deal through our ECM framework.
What is covered in the Full Insight:
  • Deal specifics
  • Deal Dynamics
  • Financial Performance
  • F351 drug and other developments
  • Scores on our framework
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top 5%
Nicholas Tan
APAC IPOs & Placements
Aequitas Research
EquitiesEquity Capital Markets
Price Chart(Sign Up to Access)
analytics-chart
x